Cure8 news brief
The study tests a new mechanism (TL1A inhibition) that may reduce inflammation and fibrosis in IBD. Positive phase 2b results suggest duvakitug could become another treatment option if later trials confirm benefit and safety.
Adults with moderately to severely active Crohn’s disease or ulcerative colitis, patients who have failed or lost response to other advanced therapies, IBD clinicians, and researchers following new drug development.
The trial randomized adults with moderately to severely active CD or UC to loading doses followed by biweekly subcutaneous duvakitug (450 mg or 900 mg) or placebo. In Crohn’s disease, endoscopic response at week 14 was achieved by 26% (450 mg) and 48% (900 mg) versus 13% with placebo.
In ulcerative colitis, duvakitug achieved higher rates of clinical remission at week 14 versus placebo (exact percentages reported in the source article). Adverse events—most commonly anemia, nasopharyngitis and headache—occurred across groups; serious adverse events were reported in some participants.
Results are from a phase 2b randomized trial (RELIEVE UCCD) reported in a news article summarizing a Lancet Gastroenterology & Hepatology paper. Phase 2 trials evaluate efficacy signals and safety but are not definitive; follow-up phase 3 trials are needed.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A new antibody, duvakitug, showed higher remission/response rates than placebo in Phase 2b study data for both ulcerative colitis and Crohn’s disease, which could lead to a new treatment option if Phase 3 trials confirm...
The Phase 2b results suggest the investigational TL1A drug duvakitug improved clinical and endoscopic outcomes versus placebo in both ulcerative colitis and Crohn’s disease, which could expand future treatment options if...
Depression is common in people with IBD and can worsen quality of life and disease outcomes. This trial explores whether mirtazapine—an antidepressant thought to have favorable gastrointestinal tolerability—can be...
